Contribution of positron emission tomography in pleural disease.

[en] INTRODUCTION: Positron emission tomography (PET) now plays a clear role in oncology, especially in chest tumours. We discuss the value of metabolic imaging in characterising pleural pathology in the light of our own experience and review the literature. BACKGROUND: PET is particularly useful in characterising malignant pleural pathologies and is a factor of prognosis in mesothelioma. Metabolic imaging also provides clinical information for staging lung cancer, in researching the primary tumour in metastatic pleurisy and in monitoring chronic or recurrent pleural pathologies. CONCLUSIONS: PET should therefore be considered as a useful tool in the diagnosis of liquid or solid pleural pathologies.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Duysinx, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Corhay, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Larock, Marie-Paule ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Withofs, Nadia ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Bury, Thierry ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie

Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire

Louis, Renaud ; Université de Liège - ULiège

Language :

English

Title :

Contribution of positron emission tomography in pleural disease.

Publication date :

2010

Journal title :

Revue des Maladies Respiratoires

ISSN :

0761-8425

eISSN :

1776-2588

Publisher :

Masson, Moulineaux Cedex 9, France

Volume :

Issue :

Pages :

e47-53

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.em-consulte.com/revue/rmr/27/8

Commentary :

Available on ORBi :

since 12 October 2011

Statistics

Number of views

211 (8 by ULiège)

Number of downloads

188 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Leung A, Muller N, Miller R. CT in differential diagnosis of diffuse pleural disease. Am J Roentgenol 1990 Mar; 154:487-92.
Dedrick CG, McLoud TC, Shepard JA, Shipley RT. Computed tomography of localized pleural mesothelioma. Am J Roentgenol 1985;144:275-80.
Light RW, Macgregor MI, Luchsinger PC, Ball WC. Pleural effusions: the diagnositic of transudates and exsudates. Ann Intern Med 1972;77:507-13.
Light RW, Erozan YS, Ball WC. Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med 1973;132:854-60.
Schönfeld N, Loddenkemper R. Pleural biopsy and thoracoscopy. Eur Respi Mon 1998;9:135-52.
Prakash U, Reiman H. Comparison of needle biopsy with cytologic analysis for the évaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985;60:158-64.
Von Hoff D, Di Volsi V. Diagnostic reliability of needle biopsy of the parietal pleura: a review of 272 biopsies. Am J Clin Pathol 1979;72:48-51.
Boutin C, Viallat JR, Rey F. Manuel pratique des techniques pleurales. France: Springer-Verlag; 1991, 59-63.
Sahn S. Malignant pleural effusions. Eur Respir Monograph 2002;22:177-88.
Antunes G, Neville E, Duffy J, on behalf of the BTS Pleural Disease Group, a subgroup of the BTS Standards of Care Committee. BTS guidelines for the management of malignant pleural effusions. Thorax 2003;58(Suppl. II): ii29-38.
Sahn S. Malignant pleural effusions. In: Fischman AP, editor. Pulmonary diseases and disorders. 2nd ed. New York: Mc Graw-Hill; 1988. p. 2159-70.
Bury T, Daenen F, Duysinx B, Bartsch P, Corhay JL. Applications en oncologie thoracique de la TEP-18 FDG. Rev Mal Respir 2001;18:623-30.
Vansteenkiste JF. Imaging in lung cancer: positron emission tomography scan. Eur Respir J Suppl 2002;35:49s-60s.
Bury T, Duysinx B, Corhay JL, Bartsch P, Rigo P. Comment j'explore... un cancer broncho-pulmonaire par imagerie metabolique (TEP-18-FDG). Rev Med Liege 2000;55:178-83.
La Tomographie à émission de positons (TEP). In: Standards Options et Recommandations: le cancer bronchopulmonaire non à petites cellules. John Libbey Eurotext; 2002, p. 86-8.
Bury T, Dowlati A, Paulus P, Corhay JL, Benoit T, Kayembe JM, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410-4. (Pubitemid 26117781)
Bury T, Paulus P, Dowlati A, Corhay JL, Weber T, Ghaye B, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560-4. (Pubitemid 26407908)
Vaylet F, Bonardel G, Salles Y, Bonnichon A, Gontier E, Margery J, et al. La tomographie par émission de positons au 18fluoro-deoxy-glucose (18FDG-TEP) et le bilan initial du cancer brocnhique. Rev Mal Respir 2005;22, 8S43-48.
Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 1998;9:397-401.
Bury T, Barreto A, Daenen F, Barthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244-7.
Bury T, Corhay JL, Duysinx B, Daenen F, Ghaye B, Barthelemy N, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376-80.
Meignan M, Paone G. La tomographie par émission de positons (TEP) au 18-fluoro-déoxy-glucose (18FDG) dans l'évaluation de la pathologie pleurale maligne. Rev Pneumol Clin 2006;62:128-34.
Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998;114:713-22.
Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T, Bartsch P, et al. Evaluation of pleural disease with 18-Fluorodeoxyglucose positron emission tomography imaging. Chest 2004;125:489-93.
Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koëter GH, et al. PET for evaluation of pleural thickening observed on CT. J Nucl Med 2004;45:995-8.
Schaffler GJ, Wolf G, Schoellnast H, Groell R, Maier A, Smolle-Jüttner FM, et al. Non-small cell lung cancer: evaluation of pleural abnomalies on CT scans with 18F FDG PET. Radiology 2004;231:858-65.
Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F, et al. 18-FDG-positron emission tomography in the evaluation of malignant pleural dieases - a pilot study. Eur J Cardio-thorac Surg 2000;17:377-83.
Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roent 2000;175:245-9.
Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U, Mullet D, et al. Clinical role of F-18 Fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002;122:1918-24.
Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF. Evaluation of pleural disease with FDG-PET imaging: preliminary report. Thorax 1997;52:187-9.
Toaff JS, Metser U, Gottfried M, Gur O, Deeb ME, Lievshitz G, et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies. Assessment with positron emission tomography-computed tomography. Investigative Radiology 2005;40:204-9.
Balogova S, Grahek D, Kerrou K, Montravers F, Younsi N, Aide N, et al. L'imagerie nucléaire au 18FDG dans les lésions pleurales en apparence isolées. Rev Pneumol Clin 2003;59:275-88.
Duysinx B, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun 2006;27:971-6.
Menda Y, Bushnell DL, Madsen MT, McLaughlin K, Kahn D, Kernstine KH. Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. Nucl Med Com 2001;22:1077-981.
Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18) F-fluoro-2-deoxy-glucosepositron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven lung cancer group. J Clin Oncol 1999;17:3201-6.
Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18:425-8.
Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000;21:707-14.
Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Pronostic value of 18F-FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 2000;41:1443-4.
Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, et al. Positron émission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:736-8.
Trail ZC, Davis RJ, Gleeson FV. Thoracic computed tomography in patients with suspected malignant pleural effusions. Clin Radiol 2001;56:193-6.
Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - a meta-analytical comparaison of PET and CT. Radiology 1999;213:530-6.
Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160-6.
Bohuslavizki KH, Klutmann S, Kröger S, Sonnemann U, Buchert R, Werner JA, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816-22.
Alberini JL, Belhocine T, Hustinx R, Daenen F, Rigo P. Wholebody positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumors (CUP syndrome). Nucl Med Commun 2003;24:1081-6.
Mantaka P, Baum RP, Hertel A, Adams S, Niessen A, Sengupta S, et al. PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic management. Cancer Biother Radiopharm 2003;18:47-58.
Rades D, Kühnel G, Wildfang I, Börner AR, Schmoll HJ, Knapp W. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individueal therapeutic management. Ann Oncol 2001;12:1605-9. (Pubitemid 34070597)
Melloni B, Monteil J, Vincent F, Bertin F, Gaillard S, Ducloux T, et al. Assessment of 18F-fluorodeoxyglucose dual-head gamma camera in asbestos lung diseases. Eur Respir J 2004;24:814-21.
Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005;127:909-15.
Weiss N, Solomon S. Talc pleurodesis mimics pleural metastases. Differentiation with positron emission tomography/computed tomography. Clin Nucl Med 2003;28:801-14.
Kwek B, Aquino S, Fischman A. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest 2004;125:2356-60. (Pubitemid 38788210)